1800-272-662
Shopping Cart 0
countryflagAU
Login

Neuroscientific Biopharmaceuticals Ltd

Healthcare AU NSB

0.093AUD
-0.005(5.10%)

Last update at 2026-03-13T04:30:00Z

Day Range

0.090.10
LowHigh

52 Week Range

0.030.26
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap30.93M
  • Volume227622
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.69612M
  • Revenue TTM0.32M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.27M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -1.84551M -1.88800M -1.06861M -10.43535M -3.17783M
Minority interest - - - - -
Net income -1.84551M 0.32M -1.06861M -10.50380M -4.19612M
Selling general administrative 0.63M 0.65M 1.77M 2.73M 1.57M
Selling and marketing expenses 0.08M 0.08M - - -
Gross profit -0.09278M -0.09134M - - -
Reconciled depreciation 0.09M 0.09M 0.06M 0.06M 0.06M
Ebit -2.00913M -1.88734M -1.06387M -10.50380M -3.17777M
Ebitda -1.91635M -1.79600M -1.00602M -10.43888M -3.11636M
Depreciation and amortization 0.09M 0.09M 0.06M 0.06M 0.06M
Non operating income net other - - - - -
Operating income -1.91729M -2.05700M -1.06387M -10.50380M -3.17777M
Other operating expenses 1.92M 2.06M 6.12M 10.50M 4.22M
Interest expense 0.00246M 0.01000M 0.00473M 0.07M 0.00006M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.17M 0.18M 0.00473M 0.07M 0.03M
Net interest income 0.16M 0.17M 0.10M 0.07M 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -2.21200M 4.96M 0.07M 1.02M
Total revenue 0.17M 2.21M 5.06M 0.07M 1.05M
Total operating expenses 1.92M 1.97M 6.12M 10.50M 4.22M
Cost of revenue 0.00047M 0.09M - - -
Total other income expense net 0.16M 0.17M 4.95M 0.07M -0.00006M
Discontinued operations - - - - -
Net income from continuing ops -1.84551M 0.32M -1.06861M -10.43535M -3.17783M
Net income applicable to common shares -1.84551M 0.32M -1.06861M -10.43535M -3.17783M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 16.96M 5.44M 5.29M 7.74M 14.83M
Intangible assets 9.57M - 0.27M 0.32M 0.37M
Earning assets - - - - -
Other current assets - 0.04M 0.05M 0.06M 0.22M
Total liab 0.15M 0.09M 0.60M 2.22M 0.22M
Total stockholder equity 16.81M 5.35M 4.69M 5.52M 14.60M
Deferred long term liab - - - - -
Other current liab - 0.00075M 0.01M 0.05M 0.05M
Common stock - 25.52M 25.27M 25.27M 25.27M
Capital stock 34.26M - 25.27M 25.27M 25.27M
Retained earnings -23.28248M -22.03833M -22.98840M -22.59798M -12.17545M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 7.27M 4.95M 4.91M 7.22M 14.16M
Cash and equivalents - - - 7.22M 14.16M
Total current liabilities 0.15M 0.09M 0.60M 2.22M 0.22M
Current deferred revenue - - - - -
Net debt - -4.95414M -4.91171M -7.21605M -14.16225M
Short term debt - - - 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 2.41M 2.84M 1.50M
Property plant equipment - - 0.00879M 0.02M 0.03M
Total current assets 7.40M 5.04M 5.01M 7.40M 14.43M
Long term investments - - - - -
Net tangible assets - - 4.42M 5.20M 14.23M
Short term investments - - - - -
Net receivables 0.07M 0.05M 0.04M 0.12M 0.05M
Long term debt - - - - -
Inventory - - - - 0.00000M
Accounts payable 0.15M 0.08M 0.59M 2.17M 0.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 1.87M 2.41M 2.84M 1.50M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.39M -0.28129M -0.33914M -0.40019M
Deferred long term asset charges - - - - -
Non current assets total 9.57M 0.39M 0.28M 0.34M 0.40M
Capital lease obligations - - - - -
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.03604M -0.00181M - -0.00387M -0.02988M
Change to liabilities - - -1.58050M 1.99M 0.11M
Total cashflows from investing activities -0.03604M -0.00181M 0.00000M -0.00387M -0.02988M
Net borrowings - - - - -
Total cash from financing activities 3.29M 0.00000M 0.00000M 0.00000M 13.51M
Change to operating activities - - -0.03330M 0.16M -0.19489M
Net income -1.84551M 0.32M -1.06861M -10.43535M -3.17783M
Change in cash 2.31M 0.04M -2.30434M -6.94620M 10.88M
Begin period cash flow 4.95M 4.91M 7.22M 14.16M 3.29M
End period cash flow 7.27M 4.95M 4.91M 7.22M 14.16M
Total cash from operating activities -0.94133M 0.04M -2.30434M -6.94233M -2.60156M
Issuance of capital stock 3.50M - - - 13.51M
Depreciation 0.09M 0.09M 0.06M 0.06M 0.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - 1.61M -2.14868M 0.08M
Change to account receivables -0.04388M -0.01102M 0.08M -0.07153M -0.03026M
Sale purchase of stock -0.21500M - 0.00000M 0.00000M 13.51M
Other cashflows from financing activities - -0.00181M - -0.00387M -0.02988M
Change to netincome - - 0.24M 1.35M 0.63M
Capital expenditures 0.00000M 0.00181M 0.00000M 0.00387M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04040M -0.50350M -1.53634M 2.08M -0.11099M
Stock based compensation 0.80M - 0.24M 1.35M 0.63M
Other non cash items 0.05M 0.55M 1.86M -0.43795M 0.66M
Free cash flow -0.94133M 0.04M -2.30434M -6.94620M -2.63144M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NSB
Neuroscientific Biopharmaceuticals Ltd		 -0.005 5.10% 0.09 - - 97.29 1.98 39.23
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.

Neuroscientific Biopharmaceuticals Ltd

216 St Georges Terrace, Perth, WA, Australia, 6000

Key Executives

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Interim CEO & CHairman 1959
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Sec. NA
Dougal Thring Chief Operating Officer NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.